Navigation Links
Some bisphosphonates users unfamiliar with drug's possible side effects on oral health
Date:5/26/2010

CHICAGO, May 26, 2010 People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning of the bones) may be unfamiliar with the drug and possible adverse side effects on oral health, according to a study in the May issue of the Journal of the American Dental Association (JADA).

Use of bisphosphonates has been associated with a small risk of developing bisphosphonate-associated osteonecrosis of the jaw (BON) that occurs spontaneously or after the patient has undergone dental surgery. BON is a rare but serious condition that can cause severe damage to the jaw bone. The prevalence of BON is between three and 12 percent for patients who receive bisphosphonates intravenously for cancer therapy and less than one percent for patients who receive bisphosphonates orally for osteoporosis or osteopenia.

In the study, the authors sought to determine whether patients taking bisphosphonates had knowledge about the medical indication for the therapy and how long the treatment would last. They also wanted to know whether participants' physicians told them about possible adverse reactions.

The researchers interviewed 73 participants (71 women, two men) seeking routine care in a dental clinic. These participants, with an average age of 66 years that ranged from 44 to 88 years, also were undergoing bisphosphonate treatment. Eighty-four percent of the participants stated they knew why they were receiving bisphosphonate therapy. However, 80 percent said they were unsure about the duration of the therapy and 82 percent could not recall receiving information about the risk of experiencing adverse reactions, including oral osteonecrosis, by their physicians.

"The results of our small study show that patients who take bisphosphonates may not be aware that BON can develop after they undergo invasive dental care," the authors wrote. "We believe that a more effective communication process between prescribing physicians, dentists and patients using bisphosphonates is needed."

The American Dental Association Advisory Committee on Medication-induced Osteonecrosis of the Jaw recommends that dental patients on bisphosphonate therapy advise their dentist. The Committee believes that it is always appropriate for physicians to encourage patients to visit the dentist regularly for professional cleanings and oral exams, as recommended by their dentist. This is especially important for patients whose oral health is put at risk from medications or medical problems.


'/>"/>

Contact: Fred Peterson
petersonf@ada.org
American Dental Association
Source:Eurekalert

Related medicine news :

1. Salesforce CRM Users Outperform Past Results by a Factor of at Least 50%
2. Hissey Kientz, LLP Warns Birth Control Pill Users Of Increased Health Risks To Those Who Have Or Are Taking YAZ or YASMIN
3. Male Abusers Often Sabotage Birth Control With Partners
4. New Chiropractic Marketing: A $1 Chiropractic Marketing Tool that Can Make Users $1000s
5. Ecstasy Users at Higher Risk of Sleep Apnea
6. New AERIUS Cell Phones Direct Microwave Signals Away from Users
7. Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil
8. Attainment Life Management & Coaching has just Debuted its Free Application for I-Phone and I-Touch Users
9. Brain scan study shows cocaine abusers can control cravings
10. Technology new gateway into treatment for problem alcohol users: Study
11. Phonak Asks Young FM Users to Tell Their Stories on YouTube
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... become Quality Insights beginning January 1, 2017. The name change aligns the ... to measuring and improving health care quality. , “We are very proud of ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced ... counsel and Eric Hoessel to vice president of sales. , Litsinger joined ...
(Date:12/8/2016)... , ... December 08, 2016 , ... David J. ... global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, ... the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... version gives development continuity to its innovative Unified Instance Manager architecture, meeting ... In addition, this new version optimizes the unattended auto-dialing system without agents, ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016 Allergy Diagnostics Market: ... and tests that are used to determine the ... milk, or drugs etc. in the samples by ... immune system. The report on global allergy diagnostics ... the market. The report consists of an executive ...
(Date:12/8/2016)... Markets has announced the addition of the "Endodontic Supplies - Global Strategic ... , ... for Endodontic Supplies in US$ Thousand. The report provides separate comprehensive analytics for ... Europe , Asia-Pacific , Latin America ... provided for the period 2015 through 2022. Also, a six-year historic analysis is ...
(Date:12/8/2016)... 2016  A Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, ... a doença do refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... Live Stretta procedure performed and broadcast during the Chinese Congress of Digestive ... , , ...
Breaking Medicine Technology: